{"title": "AS03-and MF59-Adjuvanted influenza vaccines in Children", "author": "Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard", "url": null, "hostname": null, "description": null, "sitename": "Frontiers in Immunology", "date": "2017-12-13", "cleaned_text": "382 Views | 504 Downloads Correspondence: Amanda L. Wilkins [tolson.amanda@gmail.com](mailto:tolson.amanda@gmail.com) AW, DK, GN, and EC wrote the initial drafts for the manuscript which was then revised and contributed to by BP, C-AS, and AP. C-AS has received numerous educational or research grants, including from vaccine manufacturers, although none related to this work. AP has previously conducted clinical studies on behalf of Oxford University that were sponsored by vaccine manufacturers with grants from Okairos and Pfizer closing since January 2015. His department received unrestricted educational grants from Novartis/GSK/Astra Zeneca in 2015, Pfizer/GSK/Astra Zeneca in July 2016, and Gilead/MSD/GSK/Astra Zeneca in June 2017 to support a 3-day course on Infection and Immunity in Children. He is Chair of UK Dept. Health's (DH) Joint Committee on Vaccination and Immunization (JCVI) and chair of the scientific advisory group on vaccines for the European Medicines Agency and is a member of the WHO's SAGE. The views expressed in this manuscript do not necessarily represent the views of DH, JCVI or WHO. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study was supported in part by European Commission FP7 Grant \"Advanced Immunization Technologies (ADITEC)\" and the National Institute for Health Research Oxford Biomedical Research Centre. \u00a9 "}